Patents by Inventor Paul Stark
Paul Stark has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20110064803Abstract: The present invention is directed to compositions comprising a nanoparticulate vitamin K2 having improved bioavailability. The nanoparticulate vitamin K2 particles of the composition have an effective average particle size of less than about 2000 nm and are useful in the prevention and treatment of osteoporosis. The invention also relates to a controlled release composition comprising a vitamin K2 or a nanoparticulate vitamin K2 that in operation delivers the drug in a pulsed or multi-modal manner for the prevention and treatment of osteoporosis.Type: ApplicationFiled: May 9, 2006Publication date: March 17, 2011Applicant: ELAN PHARMA INTERNATIONAL LIMITED.Inventors: John G. Devane, Paul Stark, Niall M.N. Fanning, Gurvinder Singh Rekhi, Gary Liversidge, Scott Jenkins
-
Publication number: 20110008435Abstract: The present invention provides a composition comprising ziprasidone useful in the treatment and prevention of schizophrenia and similar psychiatric disorders. In one embodiment, the composition comprises nanoparticulate particles comprising ziprasidone and at least one surface stabilizer. The nanoparticulate particles have an effective average particle size of less than about 2000 nm. In another embodiment, the composition comprises a modified release composition that, upon administration to a patient, delivers ziprasidone in a bimodal, multimodal or continuous manner. The invention also relates to dosage forms containing such compositions, and to methods for the treatment and prevention of schizophrenia and similar psychiatric disorders.Type: ApplicationFiled: February 7, 2007Publication date: January 13, 2011Applicant: Elan Corporation plcInventors: John G. Devane, Paul Stark, Niall M.M. Fanning, Gurvinder Singh Rekhi, Scott A. Jenkins, Gary Liversidge
-
Publication number: 20100247636Abstract: The present invention provides a composition comprising nilvadipine, or a salt, derivative, prodrug, or polymorph thereof, useful in the treatment and prevention of hypertension or related cardiovascular disorders. In one embodiment, the composition comprises nanoparticulate particles comprising nilvadipine, or a salt, derivative, prodrug, or polymorph thereof, and at least one surface stabilizer. The nanoparticulate particles have an effective average particle size of less than about 2000 nm. In another embodiment, the composition comprises a modified release composition that, upon administration to a patient, delivers nilvadipine, or a salt, derivative, prodrug, or polymorph thereof, in a bimodal, multimodal or continuous manner. The invention also relates to dosage forms containing such compositions, and to methods for the treatment and prevention of hypertension or related cardiovascular disorders.Type: ApplicationFiled: June 30, 2006Publication date: September 30, 2010Applicant: Elan Corporation, plcInventors: John G. Devane, Paul Stark, Niall M.M. Fanning, Gurvinder Singh Rekhi, Scott A. Jenkins, Gary Liversidge
-
Publication number: 20100136106Abstract: The invention relates to a multiparticulate modified release composition that, upon administration to a patient, delivers famciclovir in a bimodal, multimodal or continuous manner. The multiparticulate modified release composition comprises a first component and at least one subsequent component, the first component comprising a first population of active ingredient containing particles and the at least one subsequent component comprising a second population of active ingredient containing particles. The invention also relates to a solid oral dosage form containing such a multiparticulate modified release composition, and to a method for the treatment or suppression of viral infections.Type: ApplicationFiled: June 7, 2006Publication date: June 3, 2010Inventors: Gary Liversidge, Scott Jenkins, John G. Devane, Paul Stark, Niall Fanning, Gurvinder Singh Rekhi
-
Publication number: 20090297602Abstract: The invention relates to a modified release composition comprising loxoprofen or a salt or derivative thereof that in operation delivers the drug in a pulsatile or continuous manner for the treatment of pain and/or inflammation. The composition may comprise a first loxoprofen component and one subsequent loxoprofen component, wherein the first loxoprofen component comprises an immediate release component and the subsequent loxoprofen component comprises a modified release component.Type: ApplicationFiled: May 9, 2006Publication date: December 3, 2009Inventors: John G. Devane, Paul Stark, Niall M.N. Fanning, Grvinder Singh Rekhi, Gary Liversidge, Scott Jenkins
-
Publication number: 20090297597Abstract: The invention relates to a multiparticulate modified release composition that, upon administration to a patient, delivers ticlopidine in a bimodal, multimodal or continuous manner. The multiparticulate modified release composition comprises a first component and at least one subsequent component, the first component comprising a first population of active ingredient containing particles and the at least one subsequent component comprising a second population of active ingredient containing particles. The invention also relates to a solid oral dosage form containing such multiparticulate modified release composition, and to methods for inhibiting platelet aggregation, inhibiting blood clotting, and reducing risk of stroke in a patient.Type: ApplicationFiled: June 9, 2006Publication date: December 3, 2009Inventors: Gary Liversidge, Scott Jenkins, Paul Stark, Niall M.N. Fanning, Gurvinder Singh Rekhi, John G. Devane
-
Publication number: 20090297596Abstract: The present invention provides a composition comprising a platelet aggregation inhibitor, for example, cilostazol, or a salt or derivative thereof, useful in the treatment and prevention of ischemic symptoms. The invention provides a composition which comprises nanoparticulate particles comprising the platelet aggregation inhibitor and at least one surface stabilizer. The nanoparticulate particles have an effective average particle size of less than about 2000 nm. The invention provides also a composition that delivers a platelet aggregation inhibitor, or nanoparticles comprising the same, in a pulsatile or continuous manner.Type: ApplicationFiled: May 23, 2006Publication date: December 3, 2009Applicant: ELAN PHARMA INTERNATIONAL LIMITEDInventors: John Devane, Paul Stark, Niall Fanning, Gurvinder Rekhi, Scott Jenkins, Gary Liversidge
-
Publication number: 20090269400Abstract: The present invention is directed to compositions comprising a nanoparticulate antibiotic having improved bioavailability. Preferably, the antibiotic comprises nanoparticulate cephalosporin particles with an effective average particle size of less than about 2000 nm and are useful in the treatment of bacterial infection. The invention also relates to a controlled release composition comprising a cephalosporin or a nanoparticulate cephalosporin that in operation delivers the drug in a pulsed or bimodal manner for the treatment of bacterial infection. The nanoparticulate cephalosporin particles may be formulated as a controlled release drug delivery system whereby the particles are coated one or more times with one or more natural or synthetic hydrophilic or hydrophobic polymer coating materials or dispersed throughout a natural or synthetic hydrophilic and/or hydrophobic polymer matrix.Type: ApplicationFiled: May 16, 2006Publication date: October 29, 2009Applicant: ELAN PHARMA INTERNATIONAL LIMITEDInventors: John Devane, Paul Stark, Niall Fanning, Gurvinder Rekhi, Scott Jenkins, Gary Liversidge
-
Publication number: 20090017109Abstract: An article and method for reducing somnolence in a patient receiving tizanidine therapy. Tizanidine may be administered in the form of an immediate release multiparticulate composition at or around the time food is consumed. The composition may be packaged in a container for distribution.Type: ApplicationFiled: March 11, 2008Publication date: January 15, 2009Inventors: Cara A. Pellegrini, Paul Stark
-
Patent number: 7465462Abstract: A multiparticulate controlled release selective serotonin reuptate inhibitor (SSRI) formulation for oral administration is provided. The formulation includes particles of an SSRI or a pharmaceutically acceptable salt thereof, which are coated with a rate-controlling polymer that allows controlled release of the SSRI over a period of not less than about 12 hours after oral administration. The rate controlling polymer includes a film-forming water-insoluble polymer, or a mixture of a film-forming water-insoluble polymer and a film-forming water-soluble polymer.Type: GrantFiled: May 10, 2000Date of Patent: December 16, 2008Assignee: Elan Pharma International LimitedInventors: Theresa Ann Jeary, Catherine Ann Morrissey, Paul Stark
-
Publication number: 20080279929Abstract: The present invention provides a composition comprising a cefditoren, or a salt, derivative, prodrug, or other form thereof, for example, cefditoren pivoxil, useful in the treatment and prevention of infections and related conditions. The invention provides a composition which comprises nanoparticulate particles comprising the cefditoren, or a salt, derivative, prodrug, or other form thereof and at least one surface stabilizer. The nanoparticulate particles have an effective average particle size of less than about 2000 nm. The invention provides also a composition that delivers a cefditoren, or a salt, derivative, prodrug, or other form thereof, or nanoparticles comprising the same, in a pulsatile or continuous manner.Type: ApplicationFiled: February 5, 2007Publication date: November 13, 2008Applicant: Elan Corproation plcInventors: John G. Devane, Paul Stark, Nial M. N. Fanning, Gurvinder Singh Rekhi, Scott A. Jenkins, Gary Liversidge
-
Publication number: 20080206335Abstract: A multiparticulate controlled release selective serotonin reuptake inhibitor (SSRI) formulation for oral administration comprises particles of said SSRI or a pharmaceutically acceptable salt thereof coated with rate-controlling polymer which allows controlled release of said SSRI, over a period of not less than about 12 hours following oral administration. The formulation, which contains for example fluvoxamine or a pharmaceutically acceptable salt thereof, is suitable for once or twice daily administration. The formulation can comprise a blend of two or more populations of particles, pellets or mini-tablets having different in vitro and/or in vivo release characteristics.Type: ApplicationFiled: May 2, 2008Publication date: August 28, 2008Inventors: THERESA ANN JEARY, CATHERINE ANN MORRISSEY, PAUL STARK
-
Patent number: 7386352Abstract: A distributed wireless sensor network node is disclosed. The wireless sensor network node includes a plurality of sensor modules coupled to a system bus and configured to sense a parameter. The parameter may be an object, an event or any other parameter. The node collects data representative of the parameter. The node also includes a communication module coupled to the system bus and configured to allow the node to communicate with other nodes. The node also includes a processing module coupled to the system bus and adapted to receive the data from the sensor module and operable to analyze the data. The node also includes a power module connected to the system bus and operable to generate a regulated voltage.Type: GrantFiled: October 6, 2004Date of Patent: June 10, 2008Assignee: Sandia CorporationInventors: Jesse Harper Zehring Davis, Douglas Paul Stark, Jr., Christopher Patrick Kershaw, Ronald Dean Kyker
-
Publication number: 20080118556Abstract: The invention relates to a multiparticulate modified release composition that, upon administration to a patient, delivers a combination of carbidopa, levodopa and entacapone in a bimodal, multimodal or continuous manner. The multiparticulate modified release composition comprises a first component and at least one subsequent component, the first component comprising a first population of active ingredient containing particles and the at least one subsequent component comprising a second population of active ingredient containing particles. The invention also relates to a solid oral dosage form containing such a multiparticulate modified release composition, and to a method for the treatment of Parkinson's disease.Type: ApplicationFiled: June 5, 2006Publication date: May 22, 2008Applicant: Elan Corporation, plcInventors: John G. Devane, Paul Stark, Niall M. M. Fanning, Gurvinder Singh Rekhi, Gary Liversidge, Scott A. Jenkins
-
Publication number: 20080113025Abstract: The invention relates to a compositions comprising a nanoparticulate naproxen composition in combination with a multiparticulate modified release hydrocodone composition that, upon administration to a patient, delivers a hydrocodone in a bimodal or multimodal manner. The multiparticulate modified release composition comprises a first component and at least one subsequent component; the first component comprising a first population of hydrocodone-comprising particles and the at least one subsequent component comprising a second population of hydrocodone-comprising particles, wherein the combination of the components exhibit a bimodal or multimodal release profile. The invention also relates to a solid oral dosage form comprising such a combination composition.Type: ApplicationFiled: June 25, 2007Publication date: May 15, 2008Applicant: Elan Pharma International LimitedInventors: John G. Devane, Paul Stark, Niall Fanning, Gurvinder Singh Rekhi, Scott A. Jenkins, Gary Liversidge
-
Publication number: 20080102121Abstract: The invention relates to a compositions comprising a nanoparticulate meloxicam composition in combination with a multiparticulate modified release hydrocodone composition that, upon administration to a patient, delivers a hydrocodone in a bimodal or multimodal manner. The multiparticulate modified release composition comprises a first component and at least one subsequent component; the first component comprising a first population of hydrocodone-comprising particles and the at least one subsequent component comprising a second population of hydrocodone-comprising particles, wherein the combination of the components exhibit a bimodal or multimodal release profile. The invention also relates to a solid oral dosage form comprising such a combination composition.Type: ApplicationFiled: June 25, 2007Publication date: May 1, 2008Applicant: Elan Pharma International LimitedInventors: John G. Devane, Paul Stark, Niall Fanning, Gurvinder Singh Rekhi, Scott A. Jenkins, Gary Liversidge
-
Publication number: 20070160675Abstract: The present invention provides a composition comprising cephalosporin useful in the treatment and prevention of a bacterial infection. In one embodiment, the composition comprises nanoparticulate particles comprising cephalosporin and at least one surface stabilizer. The nanoparticulate particles have an effective average particle size of less than about 2000 nm. In another embodiment, the composition comprises a modified release composition that, upon administration to a patient, delivers cephalosporin in a bimodal, multimodal or continuous manner. The invention also relates to dosage forms containing such compositions, and to methods for the treatment and prevention of a bacterial infection.Type: ApplicationFiled: June 30, 2006Publication date: July 12, 2007Applicant: Elan Corporation, plcInventors: John Devane, Paul Stark, Niall Fanning, Gurvinder Rekhi, Scott Jenkins, Gary Liversidge
-
Publication number: 20060240105Abstract: The invention relates to a multiparticulate modified release composition that, upon administration to a patient, delivers at least one active ingredient in a bimodal or multimodal manner. The multiparticulate modified release composition comprises a first component and at least one subsequent component; the first component comprising a first population of active ingredient containing particles and the at least one subsequent component comprising a second population of active ingredient containing particles wherein the combination of the components exhibit a bimodal or multimodal release profile. The invention also relates to a solid oral dosage form containing such a multiparticulate modified release composition.Type: ApplicationFiled: March 10, 2006Publication date: October 26, 2006Applicant: Elan Corporation, plcInventors: John Devane, Paul Stark, Niall Fanning, Gurvinder Rekhi, Scott Jenkins, Gary Liversidge
-
Publication number: 20050277691Abstract: The present invention relates to formulations comprising a therapeutically effective amount of pravastatin, or a pharmaceutically acceptable salt thereof, and methods of their use. The present formulations and methods are designed to release little or no pravastatin in the stomach but release a therapeutic amount of pravastatin in the small intestine, thereby limiting systemic exposure of the body to pravastatin and maximizing hepatic-specific absorption of the drug. The formulations and methods of the present invention are particularly useful for treating and/or preventing conditions that are benefited by decreasing levels of lipids and/or cholesterol in the body.Type: ApplicationFiled: August 17, 2005Publication date: December 15, 2005Applicant: Biovail Laboratories, Inc.Inventors: Jackie Butler, John Devane, Paul Stark
-
Patent number: 6967218Abstract: The present invention relates to formulations comprising a therapeutically effective amount of pravastatin, or a pharmaceutically acceptable salt thereof, and methods of their use. The present formulations and methods are designed to release little or no pravastatin in the stomach but release a therapeutic amount of pravastatin in the small intestine, thereby limiting systemic exposure of the body to pravastatin and maximizing hepatic-specific absorption of the drug. The formulations and methods of the present invention are particularly useful for treating and/or preventing conditions that are benefited by decreasing levels of lipids and/or cholesterol in the body.Type: GrantFiled: January 10, 2003Date of Patent: November 22, 2005Assignee: Biovail Laboratories, Inc.Inventors: Jackie Butler, John Devane, Paul Stark